Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Reopening communities involves looking at the epidemiology

As the global COVID-19 crisis continues, countries are taking stock of the current epidemiology information on the disease and attempting to evaluate if it is safe to open their societies again. The number of new cases in several countries has slowed; however, reopening communities too soon may lead to significant spikes in case numbers at […]
Read more

Eligibility questions remain about publicly traded bio/pharma companies that received Paycheck Protection Program loans, says GlobalData

At least 49 publicly traded bio/pharmaceutical companies took Paycheck Protection Program (PPP) loans from the US Government’s $659bn program despite official guidance that the money was not intended for large public companies, says GlobalData, a leading data and analytics company. Peter Shapiro, PhD, PharmSource and Senior Director, Drugs and Business Fundamentals Databases at GlobalData, comments: […]
Read more

Scientific, ethical, legal and practical issues of immunity passports must be addressed before they become a reality

The concept of an immunity passport is under scrutiny and it is crucial that the underlying scientific, ethical, legal and practical issues must be addressed before they become a reality, says GlobalData, a leading data and analytics company. Urte Jakimaviciute, MSc, senior director of market research, commented: “Even though immunity passports could help the world […]
Read more

COVID-19 may have long-term complications and increased long-term costs on the healthcare system

As many COVID-19 patients may experience long-term complications from the illness such as intensive care unit (ICU) delirium, post-traumatic stress disorder (PTSD), lung damage, heart damage and possible neurological issues, GlobalData expects the market for these treatments to increase due to the COVID-19 pandemic as recovered patients may need long-term care for these issues after being released […]
Read more

CCR4 antagonists are a promising combinatorial agent for the future

As novel immuno-oncology (IO) drugs become established in the market, a new trend of combinatorial treatments is arising. The race to develop combinatorial drugs is increasing with more companies including IO potentiating drugs in their pipelines and investigating these in combination with established IO drugs, says GlobalData, a leading data and analytics company. Miguel Ferreira, […]
Read more

Psoriasis digital landscape for patients in Japan offers competent patient engagement, says GlobalData

In Japan, the plaque psoriasis (PsO) treatment landscape is highly competitive with the availability of conventional topical therapies, as well as biologics including anti-TNF, anti-IL-17, anti-IL-23 inhibitors, and a small molecule PDE4 inhibitor. To differentiate within this crowded market, companies offering novel therapies are using branded and unbranded channels to enhance patient engagement throughout all […]
Read more

CVMD clinical trials disrupted by COVID-19 slow to resume and investigation of diabetes drugs intensifies, says GlobalData

The clinical trial landscape has had multiple disruptions due to the COVID-19 pandemic, including the cardiovascular and metabolic disorder (CVMD) space. Despite a few trials resuming, most remain suspended or postponed indefinitely. Within the past two months, there has also been a noticeable uptick in COVID-19-related trials that are focusing on diabetes drugs, according to […]
Read more

India’s BDR Pharmaceuticals attempt to launch generic version of remdesivir looks difficult, says GlobalData

Following the news that India-based BDR Pharmaceuticals has sought the Drug Controller General of India (DCGI)’s approval to manufacture and sell the generic version of remdesivir without entering into a licensing pact with Gilead Sciences; Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “This endeavor is not new […]
Read more

Gilead’s remdesivir has potential to be stockpiled by US federal government’s National Strategic Stockpile for COVID-19

As Gilead Sciences’ remdesivir continues to steal the COVID-19 spotlight, the antiviral is likely to be considered for inclusion in the top-secret US Strategic National Stockpile (SNS) to ensure supply, according to reporting by Reynald Castañeda and Manasi Vaidya, Pharma Writers for the Investigative News team at GlobalData, a leading data and analytics company. Castañeda comments: […]
Read more

mRNA-based vaccine technology innovate approach to treating COVID-19

Messenger RNA (mRNA) based vaccine technology is emerging as one of the frontrunners among the technologies being evaluated to develop a vaccine for COVID-19, with eighteen candidates currently in development globally, according to GlobalData, a leading data and analytics company. Keshalini Sabaratnam, Pharma Analyst at GlobalData, comments: “RNA vaccines are an innovative approach as they […]
Read more

Novavax’ might trail behind Clover’s COVID-19 vaccine due to the latter’s adjuvant choice, while IMV’s vaccine does not have adjuvant boost, says GlobalData

Following the announcement that Novavax has agreed a $167m deal to acquire Praha Vaccines to aid its manufacturing capabilities for its Phase I COVID-19 vaccine candidate; Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his view: “Novavax may be at a disadvantage compared to Clover Biopharmaceuticals, which also has a protein COVID-19 […]
Read more
1 … 92 93 94 95 96 … 110